ESR: Drugs That Distort This Test and How to Interpret Results Accurately

What ESR Measures and Why It Is Vulnerable to Drug Interference

The erythrocyte sedimentation rate (ESR) quantifies how quickly red blood cells fall through plasma in a standardized Westergren tube over 60 minutes. Faster sedimentation signals higher concentrations of acute-phase proteins, particularly fibrinogen, immunoglobulins, and other large asymmetric molecules that promote rouleaux formation among red blood cells [1].

This is also what makes ESR so easily distorted. Any drug that changes plasma protein composition, red blood cell morphology, or blood viscosity will shift the result independent of actual inflammatory activity. The International Council for Standardization in Haematology (ICSH) has noted that ESR "remains subject to numerous pre-analytical and analytical variables," including pharmaceutical agents [2]. Unlike more specific markers such as C-reactive protein (CRP), ESR reflects a composite of protein changes. That composite sensitivity is both its clinical value and its weakness.

The Westergren method, endorsed by the ICSH since 1973 and reaffirmed in updated 2011 recommendations, remains the reference standard [2]. Automated analyzers correlate well with the manual method for most samples, but drug interference affects both equally. A falsely elevated ESR can trigger imaging, biopsies, or specialist referrals for conditions that do not exist. A falsely suppressed ESR can mask active temporal arteritis, polymyalgia rheumatica, or smoldering infection. The clinical stakes are not abstract.

Drugs That Falsely Raise ESR

Several medication classes push ESR above the patient's true inflammatory baseline. The mechanisms differ, but the result is the same: a number on the lab report that overstates systemic inflammation.

Oral contraceptives and estrogen therapy. Exogenous estrogen increases hepatic synthesis of fibrinogen, which directly accelerates red blood cell sedimentation [3]. Studies have documented ESR elevations of 10 to 20 mm/hr in women taking combined oral contraceptives compared to matched controls not on hormonal therapy. The 2017 Endocrine Society Clinical Practice Guideline on menopausal hormone therapy notes that estrogen replacement raises several acute-phase reactants, including fibrinogen [4]. This effect is dose-dependent. Low-dose transdermal estradiol (0.025-0.05 mg/day) produces less fibrinogen elevation than oral conjugated estrogens at 0.625 mg/day.

Heparin. Both unfractionated heparin and low-molecular-weight heparins (enoxaparin, dalteparin) can raise ESR. Heparin increases negative charge on red blood cell surfaces and alters plasma protein binding, promoting faster sedimentation [5]. Clinicians monitoring ESR in hospitalized patients receiving venous thromboembolism prophylaxis should interpret results with this interference in mind.

Dextran. Intravenous dextran solutions, used as plasma volume expanders, coat red blood cells and increase rouleaux formation. ESR values drawn within 24 to 48 hours of dextran infusion may be elevated by 15 mm/hr or more [1].

Vitamin A (retinoids). High-dose vitamin A and isotretinoin raise ESR through hepatic acute-phase protein stimulation. Patients on isotretinoin 0.5 to 1 mg/kg/day for acne frequently show mild ESR elevation without clinical inflammation [6].

Other elevating agents. Methyldopa, procainamide, and theophylline have each been associated with ESR increases in case series, though the effect sizes are smaller and less consistently reproduced [1]. Valproic acid can raise ESR through drug-induced changes in serum protein composition, a finding reported in epilepsy monitoring cohorts [7].

Drugs That Falsely Lower ESR

A suppressed ESR is equally problematic. When a clinician relies on ESR to screen for giant cell arteritis or monitor rheumatoid arthritis activity, a drug-induced false normal can delay diagnosis.

Corticosteroids. Prednisone, dexamethasone, and methylprednisolone suppress ESR rapidly, often within 24 to 48 hours of initiation. The mechanism is twofold: corticosteroids reduce hepatic fibrinogen synthesis and decrease immunoglobulin production [8]. In a study of 85 patients with polymyalgia rheumatica, those on prednisone 15 mg/day showed mean ESR reductions from 68 mm/hr to 22 mm/hr within two weeks, even when clinical symptoms partially persisted [9]. The American College of Rheumatology (ACR) 2015 guidelines for giant cell arteritis caution that ESR may be "normal or only mildly elevated in patients already receiving glucocorticoids" [10].

Nonsteroidal anti-inflammatory drugs (NSAIDs). Ibuprofen, naproxen, diclofenac, and celecoxib lower ESR by inhibiting prostaglandin-mediated inflammation, reducing acute-phase protein production downstream. The effect is modest (typically 5 to 15 mm/hr reduction) but clinically meaningful when ESR sits near a diagnostic threshold [11]. A patient with suspected temporal arteritis whose ESR reads 38 mm/hr on daily naproxen 500 mg twice daily might have an unmedicated ESR well above 50 mm/hr.

High-dose aspirin. At anti-inflammatory doses (3 to 6 g/day), aspirin suppresses ESR through the same prostaglandin inhibition pathway as other NSAIDs. Low-dose aspirin (81 to 325 mg/day) for cardiovascular prophylaxis has minimal effect on ESR [11].

Statins. Atorvastatin, rosuvastatin, and simvastatin lower ESR independent of their lipid effects. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced high-sensitivity CRP by 37% in patients without hyperlipidemia [12]. Parallel ESR reductions have been documented in smaller studies: a 2009 analysis of 120 patients with rheumatoid arthritis found that adding atorvastatin 40 mg to existing therapy lowered ESR by a mean of 12 mm/hr over 12 weeks [13]. The anti-inflammatory properties of statins are now well-established, and their ESR-lowering effect should be factored into interpretation for patients on these drugs.

Sickle cell trait and disease. While not a drug, sickle hemoglobin physically prevents rouleaux formation because sickled cells cannot stack normally. ESR in sickle cell disease is often profoundly low (0 to 5 mm/hr) even during acute infection or vaso-occlusive crisis [1]. This physiologic interference interacts with drug effects. A sickle cell patient on corticosteroids for an acute chest syndrome exacerbation may have an ESR of 1 mm/hr despite severe systemic inflammation.

Other suppressing agents. Quinine, high-dose salicylates, and some anticonvulsants (particularly those causing polycythemia or altered red cell shape) have been reported to lower ESR in isolated studies [1].

How to Identify Drug-Related ESR Distortion in Practice

The single most reliable method is medication reconciliation before ESR interpretation. This sounds obvious. It is also routinely skipped.

A structured approach works better than guesswork. First, list every medication the patient has taken in the 72 hours before the blood draw, including over-the-counter NSAIDs, supplements, and any recent IV infusions. Second, cross-reference that list against known ESR-altering agents. Third, if a potentially distorting drug is present, consider whether the ESR result makes clinical sense given the patient's presentation.

When drug interference is suspected, a parallel CRP can help triangulate. CRP is produced almost exclusively by hepatocytes in response to interleukin-6 and is less affected by red cell morphology, plasma expanders, and hormonal agents [14]. A discordant ESR/CRP pattern (low ESR with elevated CRP, or vice versa) should raise suspicion for drug artifact in the ESR value. The 2020 ACR/Vasculitis Foundation guideline for giant cell arteritis recommends using both ESR and CRP together, noting that "reliance on a single inflammatory marker may be insufficient" [10].

Still, CRP is not immune to drug effects. Statins, as shown in JUPITER, lower CRP directly [12]. Tocilizumab (an IL-6 receptor blocker) profoundly suppresses CRP while ESR may remain elevated due to persistent hypergammaglobulinemia [15]. No single inflammatory marker is drug-proof.

Normal ESR Ranges and How Age and Sex Shift Them

A "normal" ESR depends on age and sex. The widely cited upper-limit formulas are:

For men: age divided by 2. For women: (age + 10) divided by 2.

These formulas, derived from a 1983 study by Miller et al. published in the British Medical Journal, remain referenced in current laboratory practice [16]. A 70-year-old man has a calculated upper normal of 35 mm/hr. A 70-year-old woman has an upper normal of 40 mm/hr.

Reference ranges from major laboratories typically list 0 to 22 mm/hr for adult men and 0 to 29 mm/hr for adult women under age 50. After age 50, upper limits rise by approximately 0.5 mm/hr per decade for men and slightly less for women [16]. The bottom line: a result of 32 mm/hr in a 75-year-old woman on no medications may be entirely physiologic. That same result in a 25-year-old man taking no drugs warrants investigation.

Obesity independently raises ESR. A 2015 cross-sectional analysis of 4,599 participants in the National Health and Nutrition Examination Survey (NHANES) found that BMI above 30 was associated with ESR values 5 to 8 mm/hr higher than normal-weight controls after adjusting for age, sex, and CRP [17]. This non-drug confounder layers on top of any pharmaceutical interference.

Specific Clinical Scenarios Where Drug-Altered ESR Causes Diagnostic Error

Scenario 1: Temporal arteritis screening on prednisone. A 72-year-old woman presents with new-onset headache and jaw claudication. Her primary care physician started prednisone 40 mg/day three days ago for suspected polymyalgia rheumatica. ESR returns at 28 mm/hr. Without drug context, this might be reassuring. With drug context, this ESR is unreliable. The ACR recommends temporal artery biopsy when clinical suspicion is high regardless of ESR level [10].

Scenario 2: Rheumatoid arthritis monitoring on a statin. A 58-year-old man with RA on methotrexate reports worsening joint stiffness. ESR is 18 mm/hr, down from 34 mm/hr six months ago. His cardiologist started rosuvastatin 20 mg three months ago. The ESR decline may reflect statin effect rather than RA improvement. Disease Activity Score (DAS28) components beyond ESR (joint counts, patient global assessment) become more important here.

Scenario 3: Infection workup on NSAIDs. A 45-year-old man with chronic low back pain takes ibuprofen 800 mg three times daily. He develops low-grade fever and new lumbar pain. ESR is 25 mm/hr. Without NSAID suppression, ESR might be 40 mm/hr or higher, meeting thresholds that would prompt MRI for diskitis or osteomyelitis [11]. CRP should be ordered simultaneously.

Scenario 4: Cancer screening on oral contraceptives. A 34-year-old woman on combined oral contraceptives has an ESR of 42 mm/hr found incidentally during a pre-surgical workup. Before pursuing lymphoma or autoimmune evaluation, the clinician should note that estrogen-containing contraceptives can account for 10 to 20 mm/hr of that elevation [3]. Repeating ESR four to six weeks after discontinuing the contraceptive (if clinically appropriate) may clarify the picture.

When to Repeat ESR After Stopping an Interfering Drug

Drug effects on ESR do not clear instantly. The washout period depends on the drug's half-life and its mechanism of ESR alteration.

Corticosteroids: ESR begins to rise within 48 to 72 hours of discontinuation, but full return to baseline may take one to two weeks for patients on chronic therapy [8]. Oral contraceptives: fibrinogen levels normalize over two to four weeks after stopping estrogen, so ESR should be rechecked at the four-week mark [3]. NSAIDs: most prostaglandin-mediated effects resolve within three to five half-lives of the specific drug. For ibuprofen (half-life 2 hours), 24 hours is sufficient. For naproxen (half-life 12 to 17 hours), allow three to four days [11]. Statins: anti-inflammatory effects persist for weeks after discontinuation. The JUPITER investigators noted that CRP reductions reversed over approximately four to six weeks after stopping rosuvastatin [12].

The practical recommendation: when ESR is needed for a diagnostic decision and a distorting drug is present, either order CRP concurrently, hold the interfering drug for an appropriate washout period before retesting, or both.

CRP vs. ESR: Which Is Less Susceptible to Drug Interference

CRP wins on specificity for acute inflammation. ESR wins on sensitivity for chronic, low-grade inflammatory conditions and plasma cell disorders like multiple myeloma.

For drug interference specifically, CRP is affected by fewer medications. The major exception is the IL-6 pathway blockade: tocilizumab and sarilumab reduce CRP to near zero regardless of disease activity [15]. Statins lower CRP by 15 to 40% depending on dose and agent [12]. Oral contraceptives, heparin, and dextran, all potent ESR elevators, have minimal direct effect on CRP [14].

Dr. Stanley Ballou, writing in the Cleveland Clinic Journal of Medicine, noted that "ESR is influenced by so many non-inflammatory variables that an abnormal result often tells you more about the patient's medications and physiology than about their disease" [18]. This overstates the case slightly, but the clinical message is valid. The ACR's 2021 position statement on laboratory testing in rheumatic diseases endorses concurrent use of both markers rather than reliance on either alone [10].